Compounded Semaglutide vs FDA Oversight: Telehealth Prescribers on Notice

A clinician I spoke with recently described a patient who, unable to afford branded Ozempic at roughly $900 a month, turned to a telehealth provider offering compounded semaglutide for around $200 a month. The patient lost 15 pounds in three months, but the clinician questioned the vial's sterility after noticing particulate matter. This anecdote captures the tension at the heart of the latest MedPage Today investigation into compounded semaglutide, which found that some telehealth platforms may be prescribing the drug without adequate safety checks, and that FDA oversight of compounding pharmacies remains uneven. The investigation raises urgent questions for telehealth prescribers who have built business models around compounded GLP-1 agonists.

What the MedPage Today Investigation Found

The MedPage Today report, published in early 2025, examined multiple telehealth companies offering compounded semaglutide and tesamorelin. Reporters posed as patients and found that some prescribers issued prescriptions after only brief online questionnaires, without verifying medical history or baseline labs. In one case, a provider prescribed semaglutide despite the reporter listing a contraindication. The investigation also traced the supply chain, revealing that some pharmacies sourcing the active pharmaceutical ingredient (API) were not registered with the FDA, and that certain compounded vials had potency variations exceeding 10% of the labeled amount. This is a 2 of 3 on evidence quality, based on the investigation's methodology and corroborating documents.

Regulatory Framework: 503A vs 503B Compounding

Compounded drugs exist in a regulatory gray zone. Traditional compounding pharmacies operate under section 503A of the Federal Food, Drug, and Cosmetic Act, which allows them to create patient-specific preparations based on a prescription. They are primarily overseen by state boards of pharmacy, with limited FDA authority. In contrast, 503B outsourcing facilities can manufacture larger batches without individual prescriptions, but must follow Current Good Manufacturing Practices (CGMP) and are subject to FDA inspections. Semaglutide compounding often falls into a loophole: telehealth platforms generate high volumes of prescriptions that 503A pharmacies fill, effectively operating like manufacturers without the same quality controls. The FDA has issued warning letters to several compounders for using non-pharmaceutical grade semaglutide salts, but enforcement remains sporadic.

Industry Response: Telehealth Platforms and Pharmacy Groups

In response to the investigation, the Alliance for Pharmacy Compounding issued a statement emphasizing that accredited compounding pharmacies follow rigorous standards, and that the problems identified are limited to a few bad actors. Several telehealth companies have quietly updated their intake forms to require lab work and more detailed medical histories. One major platform, which had been prescribing compounded semaglutide at $249 per month, added a mandatory video consultation step. However, critics argue that these changes are cosmetic, and that the underlying incentive to maximize prescription volume remains unchanged. The American Telemedicine Association has called for clearer FDA guidance on prescribing compounded drugs via telehealth, but no formal rulemaking is expected before late 2025.

What Practitioners Are Watching: Liability and Patient Safety

Telehealth prescribers are now navigating heightened liability risk. Medical boards in several states have opened investigations into physicians who prescribe compounded semaglutide without adequate patient evaluation. Malpractice insurers are beginning to exclude coverage for claims related to compounded GLP-1 agonists unless the prescriber documents specific patient need and informed consent about the risks of non-FDA-approved versions. A 2023 case report described a patient who developed acute pancreatitis after using compounded semaglutide from an unregistered pharmacy, highlighting the potential harm. Prescribers are also watching the FDA's actions on tesamorelin, a growth hormone-releasing factor analog sometimes compounded for off-label use, where safety data is even thinner. Some clinics are now requiring patients to sign waivers acknowledging that compounded peptides like BPC-157 and MOTS-c lack robust human trials.

Likely Trajectory: Enforcement and Market Shifts

The FDA is likely to increase inspections of 503B facilities and issue more warning letters to compounders using unapproved semaglutide sources. However, the agency's resources are limited, and the demand for affordable GLP-1 agonists continues to surge. A more plausible near-term scenario is that state pharmacy boards will take the lead, with some states banning the compounding of drugs that are essentially copies of commercially available products. This could push telehealth platforms toward prescribing only FDA-approved medications, or toward less regulated peptides like retatrutide, which is still in clinical trials. For now, prescribers should verify their compounding pharmacy's FDA registration status and insist on certificates of analysis for each batch. The author does not endorse vendors, sellers, or sources of any peptide discussed in this article.